Clinical Report: Improvement in Photophobia Symptoms with Galcanezumab Treatment
Overview
This study evaluated the impact of galcanezumab on photophobia in patients with episodic and chronic migraine. Significant reductions in photophobia symptoms were observed, alongside improvements in headache frequency and associated disability.
Background
Photophobia is a prevalent and debilitating symptom in migraine patients, affecting their quality of life. Despite its clinical significance, the effects of specific treatments on photophobia have not been thoroughly investigated. Galcanezumab, a CGRP monoclonal antibody, has emerged as a potential therapeutic option for migraine management.
Data Highlights
Measure
Baseline
Month 3
P-value
Monthly Headache Days (MHDs)
15
4
< 0.001
UPSIS-12 Score Reduction
-
22.6%
< 0.001
Key Findings
77 patients were enrolled, with 47 completing the study.
Monthly headache days decreased from a median of 15 to 4 days by month 3 (p < 0.001).
74.5% of patients were classified as responders with a ≥50% reduction in headache frequency.
Significant reduction in ictal photophobia was observed in responders (p = 0.010).
Improvements were noted in headache intensity, attack duration, and psychological comorbidities.
No serious adverse events were reported during the treatment period.
Clinical Implications
The findings indicate that galcanezumab may reduce photophobia in migraine patients.
Conclusion
Galcanezumab demonstrates significant efficacy in reducing migraine symptoms and photophobia.
